Company description: OXB is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 30 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patients cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Job description: Join Us in Changing Lives At OXB, our people are at the heart of everything we do. Were on a mission to enable life-changing therapies to reach patients around the worldand were looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful. Were currently recruiting for aTechnical Writer to join our Process Development team. The purpose of this role is to collaborate with Scientists in the effective reporting of experimental data from work carried out within the PD department, playing a key part in advancing our mission and making a real difference. Your responsibilities in this role would be: Preparation and authoring of clear and concise documentation including protocols and scientific reports to support Upstream and Downstream process development activities. Standardisation of PD documentation to ensure technical presentations, protocols and reports meet OXB and client needs and are delivered within project timelines. Support digitisation programmes aimed to reduce report turnaround times and ensure consistent, compliant reports. Maintain a high standard of record keeping so that information is clearly captured, disseminated, and reported. Disseminate critical findings which may have a business impact to other departments within the company. Function as a department Technical Writing Subject Matter Expert, this includes the delivery of technical writing training to the department. Ensure all scientific or proprietary data is submitted or recorded in appropriate official documentation. Maintain a high ethical standard and a commitment to producing high quality work. We are Looking For: A graduate or postgraduate degree (or equivalent level qualification) in a relevant science Previous operational experience within a Process development or GMP Manufacturing environment. A sound understanding of basic biopharmaceutical process development activities. Industry experience in authoring biopharma process development reports would be advantageous. A high standard or of written and verbal communication skills in English. The ability to collaborate cross departmentally to achieve PD departmental goals. Highly organised and the ability to manage multiple tasks & projects. Excellent organisational and time management skills About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 30 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the worlds most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXBs world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. Why Join Us? ??Competitive total reward packages ??Wellbeing programsthat support your mental and physical health ??Career development opportunitiesto help you grow and thrive ??Supportive, inclusive, and collaborative culture ??State-of-the-art labs and manufacturing facilities ?? A company that lives its values: Responsible, Responsive, Resilient, Respect We want you to feel inspired every day. At OXB, were future-focused and growing fast. We succeed togetherthrough passion, commitment, and teamwork. Ready to Make a Difference? Profile description: ,, We offer: Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patients cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.